Beyond Air

XAIR

Market cap $5.73M

GARDEN CITY, N.Y., April 15, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced that Robert Goodman, Chief Executive Officer, and Dan Moorhead, Chief Financial Officer of Beyond Air, will participate in the D. Boral Capital Global Conference 2026, which is being held on Thursday, May 7th, at The Plaza Hotel in New York.

Data was published in the Online Itinerary Planner for the 2026 AACR Annual Meeting, and is scheduled to be presented at the meeting on April 19th Data was published in the Online Itinerary Planner for the 2026 AACR Annual Meeting, and is scheduled to be presented at the meeting on April 19th

GARDEN CITY, N.Y., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today commented on the publication of an independent review article providing the most comprehensive overview to date of high‑dose inhaled nitric oxide (iNO) delivered at concentrations well above the FDA‑approved 20 ppm, and presenting mounting evidence that high‑dose iNO may function as a novel broad‑spectrum antimicrobial therapy for a wide range of respiratory infections. Titled “The therapeutic potential of high‑dose inhaled nitric oxide for antimicrobial effects: a narrative review and future directions,” the article was published in Intensive Care Medicine Experimental (ICMx), a peer-reviewed, open-access journal of the European Society of Intensive Care Medicine, published by Springer Nature Switzerland AG.

Beyond Air, Inc. (XAIR) Q3 2026 Earnings Call Transcript

Increased revenue by 105% year-over-year (YoY) to $2.2 million in fiscal Q3 Maintain fiscal year 2026 revenue guidance of $8-10 million $22.3 million pro forma cash, cash equivalents, restricted cash and marketable securities, including net proceeds from recent PIPE transaction, expected to provide runway into calendar 2027 Signed binding letter of intent for XTL Biopharmaceuticals to acquire 85% of Beyond Air's subsidiary NeuroNOS; Beyond Air to receive up to $32.5 million from the combination of upfront cash, development and commercial milestones and 19.99% equity ownership in XTL Biopharmaceuticals Phase 1a data from UNO program in solid tumors to be presented at AACR Annual Meeting in April 2026 Conference call at 8:00 a.m. ET today, February 13 th    GARDEN CITY, N.Y.

GARDEN CITY, N.Y., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide to improve the lives of patients, today announced that Steve Lisi, Chairman & Chief Executive Officer of Beyond Air, will participate in the 13th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference being held February 9th to 11th in Snowbird, UT and the Noble Capital Markets Emerging Growth Virtual Equity Conference being held February 4th to 5th.

Unmatched scientific firepower: Two Nobel Laureates join Founder Prof. Haitham Amal, leading global autism researcher Critical unmet need: 1 in 31 U.S. children now affected, zero FDA-approved disease-modifying therapies exist FDA Orphan Drug designations secured for autism-related Phelan-McDermid Syndrome (PMS) and Glioblastoma Platform targets the core biology of autism, not just symptomatic relief Beyond Air (NASDAQ: XAIR), majority owner of NeuroNOS, to hold 19.99% of XTL's post-transaction share capital Beyond Air to receive up to $32.5 million in upfront, development and commercial milestone payments TEL AVIV and BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd.

GARDEN CITY, N.Y., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Doug Larson has resigned as Chief Financial Officer to pursue another opportunity.

Beyond Air, Inc. ( XAIR ) Q2 2026 Earnings Call November 10, 2025 4:30 PM EST Company Participants Steven Lisi - CEO & Chairman of the Board Douglas Larson - Chief Financial Officer Conference Call Participants Garth Russell - Lifesci Advisors, LLC Justin Walsh - JonesTrading Institutional Services, LLC, Research Division Yale Jen - Laidlaw & Company (UK) Ltd., Research Division Sam Eiber - BTIG, LLC, Research Division Presentation Operator Good afternoon, and welcome to the Beyond Air financial results call for the fiscal quarter ended September 30, 2025.

Increased revenue by 128% year over year (YoY) to $1.8 million Appointed Beyond Air Board member Bob Goodman as Interim Chief Commercial Officer Raised $12.0 million in debt financing; proforma cash, cash equivalents, restricted cash and marketable securities of $22.9 million as of September 30, 2025 Achieves certificate for Medical Device Single Audit Program (MDSAP) Updated fiscal year 2026 revenue guidance to $8 – $10 million Conference call at 4:30 p.m. ET today, November 10 th GARDEN CITY, N.Y.